uniQure (QURE) Price Targets Raised by Analysts After Positive Trial Results

uniQure N.V. (NASDAQ:QURE) is one of the 12 Best Performing Stocks in the Last 3 Months. On October 8, RBC Capital reiterated a Buy rating on uniQure N.V. (NASDAQ:QURE) and increased its price target from $55 to $65.

Moreover, on October 6, H.C. Wainwright also raised its price target on uniQure N.V. (NASDAQ:QURE) from $70 to $110 and kept a Buy rating.

These updates came after the company reported positive topline data from its Phase I/II study of AMT-130 for treating Huntington’s disease on September 24. The data showed that its gene therapy, AMT-130, slowed down the progression of Huntington’s disease.

According to the report, this pivotal study met the primary endpoint and showed that a high dose of AMT-130 slowed the disease by 75% over 36 months. uniQure N.V. (NASDAQ:QURE) also said that the treatment was generally safe and well-tolerated.

Currently, there are no approved therapies to delay the onset or slow the progression of Huntington’s disease. uniQure N.V.’s (NASDAQ:QURE) AMT-130 could significantly change the treatment landscape for this disease

The FDA has granted AMT-130 a special designation as a Breakthrough Therapy designation and Regenerative Medicine Advanced Therapy (RMAT). uniQure N.V. (NASDAQ:QURE) expects to submit a biologics license application (BLA) in the first quarter of 2026 and plans to launch the treatment in the US later that year after approvals.

uniQure N.V. (NASDAQ:QURE) is a Dutch biotechnology company focused on developing gene therapies for serious diseases.

While we acknowledge the potential of QURE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best American AI Stocks to Buy According to Analysts and 11 Dirt Cheap Stocks to Buy According to Analysts.

Disclosure: None. This article is originally published at Insider Monkey.